Clinical Trial Update: Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating neoadjuvant S-1 with concurrent radiotherapy for borderline resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Japan Adjuvant Study Group of Pancreatic Cancer | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED